General Information of DTT (ID: TTPM6HI)

DTT Name Interleukin-1 alpha (IL1A) DTT Info
Gene Name IL1A

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Discontinued Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
5 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
MABp1 DM8D13S Colorectal cancer 2B91.Z Phase 3 [1]
Xilonix DMK34MZ Colorectal cancer 2B91.Z Phase 3 [2]
ABT-981 DM6PTIX Osteoarthritis FA00-FA05 Phase 2 [3]
Bermekimab DM7A592 Hidradenitis suppurativa ED92.0 Phase 2 [4]
Natrunix DMBRSWJ Arthritis FA20 Phase 2 [5]
------------------------------------------------------------------------------------
2 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
IX207-887 DM4TE8R Rheumatoid arthritis FA20 Discontinued in Phase 2 [6]
IL1aQb DMKS4Z9 Arteriosclerosis BD40 Terminated [7]
------------------------------------------------------------------------------------
1 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Interleukin-1-alpha - Amgen/Roche DMB9AIX Discovery agent N.A. Investigative [8]
------------------------------------------------------------------------------------
Molecule Interaction Atlas

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of xbiotech.
3 Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1alpha and IL-1beta. MAbs. 2015;7(3):605-19.
4 Target molecules for future hidradenitis suppurativa treatment. Exp Dermatol. 2021 Jun;30 Suppl 1:8-17.
5 ClinicalTrials.gov (NCT05363917) Phase II Double-Blinded, Placebo-Controlled Randomized Study Examining the Safety and Efficacy of Natrunix Versus Methotrexate (+Folate) for the Treatment of Rheumatoid Arthritis. U.S.National Institutes of Health.
6 Inhibition of interleukin-1 release by IX 207-887. Agents Actions. 1990 Jun;30(3-4):350-62.
7 Cytos Biotechnology AG - Product Pipeline Review - 2013. Global Markets Direct. Dec 2013.
8 Identification of regions in interleukin-1 alpha important for activity. J Biol Chem. 1993 Oct 15;268(29):22105-11.